RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Stock Short Interest Drops 74.8%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 107 shares, a decline of 74.8% from the October 15th total of 425 shares. Based on an average daily volume of 660 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

RCN Pareto Strategic Allocation ETF Stock Performance

NYSEARCA:PRTO opened at $27.07 on Thursday. The stock’s fifty day moving average price is $27.33. RCN Pareto Strategic Allocation ETF has a 52-week low of $24.68 and a 52-week high of $28.58. The firm has a market cap of $17.25 million, a P/E ratio of -28.20 and a beta of 0.92.

RCN Pareto Strategic Allocation ETF Company Profile

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients. One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.